ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition
"ImmunoGen is advancing experimental therapies expected to make a
meaningful difference for patients with cancer, and we believe the
preclinical data being presented at ASH with our IMGN529 and IMGN779
help demonstrate the potential significance of these programs," said Dr.
In addition to these data presentations on ImmunoGen's wholly owned
compounds, clinical data will be presented with Sanofi's CD38-targeting
antibody isatuximab (
Title: "IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergystic Activity with Rituximab in Non-Hodgkin Lymphona (NHL) Models"
-
Poster session #625:
Saturday, Dec. 5 ,5:30-7:30 pm ET . Abstract #1548.
Title: "IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells"
-
Poster session #616:
Saturday, Dec. 5 ,5:30-7:30 pm ET . Abstract #1366.
Title: "A Dose Finding Phase II Trial of Isatuximab (
-
Oral presentation #653:
Mon., Dec. 7 ,8:00 am . Abstract #509.
Additional information can be found at www.hematology.org, including abstracts.
About
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop novel anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including IMGN529, IMGN779, and isatuximab (
View source version on businesswire.com: http://www.businesswire.com/news/home/20151201005414/en/
info@immunogen.com
Source:
News Provided by Acquire Media